Alexion Receives NORD “Partners in Progress” Award for Soliris in aHUS
Alexion was honored by the National Organization for Rare Disorders (NORD) with a “Partners in Progress” Corporate Award for bringing to market the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS).
The award was given at the NORD gala in Washington, D.C. on May 15th, an annual event that honors government officials, patient advocates, medical researchers, and companies that have made a difference in the lives of patients with rare diseases.